Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end.
Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end.